多西紫杉醇联合泼尼松治疗激素抵抗性前列腺癌的疗效分析  

Effect of Docetaxel Combined with Prednisone for Treatment of Hormone-refractory Prostate Cancer Patients

作　　者：李勇 徐志刚 张小平 楚昌彬 尹志康[2] LI Yong;XU Zhigang;ZHANG Xiaoping;CHU Changbin;YIN Zhikang(Department of Urology, Chongqing Red Cross Hospital / People's Hospital of Jiangbei District, Chongqing, 400020, China;Department of Urology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China)

机构地区：[1]重庆市红十字会医院/江北区人民医院泌尿外科,重庆400020 [2]重庆医科大学附属第一医院泌尿外科,重庆400016

出　　处：《肿瘤药学》2017年第6期743-746,共4页Anti-Tumor Pharmacy

基　　金：重庆市卫生计生委医学科研项目(1201096)

摘　　要：目的探讨多西紫杉醇联合泼尼松治疗激素抵抗性前列腺癌的疗效及对患者生存状态的影响。方法收集2008年5月~2011年9月间本院收治的激素抵抗性前列腺癌患者67例,回顾治疗方案并将患者分为接受米托蒽醌联合泼尼松治疗的对照组35例、接受多西紫杉醇联合泼尼松治疗的观察组32例,持续治疗6疗程。评估两组疗效,检测血清肿瘤标志物含量;随访5年并记录两组生存时间及生存率。结果治疗6疗程后,观察组治疗有效率显著高于对照组,血清肿瘤标志物PSA、PSAP、CEA含量显著低于对照组,差异均有统计学意义(P<0.05);观察组平均生存时间显著长于对照组,1年、5年生存率显著高于对照组,差异均有统计学意义(P<0.05)。结论多西紫杉醇联合泼尼松可提高激素抵抗性前列腺癌的疗效、降低肿瘤恶性程度,延长患者生存时间并提高5年生存率。Objective To study the effect of Docetaxel combined with Prednisone for treatment of hormone-refractory prostate cancer patients and their influence on survival condition.Methods67hormone-refractory prostate cancer patients were chosen as research subjects in our hospital during May2008to September2011,treatment schemes were reviewed and patients were divided into control group(n=35)who underwent mitoxantrone and prednisone treatment and observation group(n=32)who underwent docetaxel plus prednisone treatment,both were lasted for6courses.After treatment,the curative effect of patients in the two groups was evaluated,serum tumor markers were detected,the survival time and survival rate were recorded during5years follow-up.Results after treatment for6courses,treatment efficiency of patients in observation group was higher than that in control group,serum tumor markers such as PSA,PSAP and CEA were lower than those in control group(P<0.05);5years follow-up and the average survival time in observation group were longer than that in control group,1-year survival rate and5-year survival rate were higher than those in control group(P<0.05).Conclusion Docetaxel combined with prednisone can improve curative effect of patients with hormone-refractory prostate cancer,reduce the malignant degree of tumor,prolong the survival time and improve the5-year survival rate.

关 键 词：激素抵抗性前列腺癌 多西紫杉醇 泼尼松 生存状态 

分 类 号：R737.25[医药卫生—肿瘤]